Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets
Open accessAbstract
Background & aims Nonalcoholic fatty liver disease is a common consequence of human and rodent obesity. Disruptions in lipid metabolism lead to accumulation of triglycerides and fatty acids, which can promote inflammation and fibrosis and lead to nonalcoholic steatohepatitis. Circulating levels of fibroblast growth factor (FGF)21 increase in patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis; therefore, we assessed the role of FGF21 in the progression of murine fatty liver disease, independent of obesity, caused by methionine and choline deficiency.Methods C57BL/6 wild-type and FGF21-knockout (FGF21-KO) mice were placed on methionine- and choline-deficient (MCD), high-fat, or control diets for 8-16 weeks. Mice were weighed, and serum and liver tissues were collected and analyzed for histology, levels of malondialdehyde and liver enzymes, gene expression, and lipid content.Results The MCD diet increased hepatic levels of FGF21 messenger RNA more than 50-fold and serum levels 16-fold, compared with the control diet. FGF21-KO mice had more severe steatosis, fibrosis, inflammation, and peroxidative damage than wild-type C57BL/6 mice. FGF21-KO mice had reduced hepatic fatty acid activation and β-oxidation, resulting in increased levels of free fatty acid. FGF21-KO mice given continuous subcutaneous infusions of FGF21 for 4 weeks while on an MCD diet had reduced steatosis and peroxidative damage, compared with mice not receiving FGF21. The expression of genes that regulate inflammation and fibrosis were reduced in FGF21-KO mice given FGF21, similar to those of wild-type mice.Conclusions FGF21 regulates fatty acid activation and oxidation in livers of mice. In the absence of FGF21, accumulation of inactivated fatty acids results in lipotoxic damage and increased steatosis.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
FGF21 seems to serve as a protective factor that limits hepatic toxicity and dysfunction.
“Altogether, FGF21 seems to serve as a protective factor that limits hepatic toxicity [141,167] and dysfunction [168].”
From Hepatokines and metabolism: Deciphering communication from the liver (2021) · cites this paper as [167]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · see citing works
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664 · see citing works
FGF-21 as a novel metabolic regulator
Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23606 · Cited by 2,125 · see citing works
Pathogenesis of Liver Fibrosis
Hernandez-Gea, V., & Friedman, S. L. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130246 · Cited by 1,809 · see citing works
Lipid Droplets and Cellular Lipid Metabolism
Walther, T. C., & Farese, R. V. (2012) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061009-102430 · Cited by 1,668 · see citing works
Inagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., Li, Y., Goetz, R., Mohammadi, M., Esser, V., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.003 · Cited by 1,504 · see citing works
Badman, M. K., Pissios, P., Kennedy, A. R., Koukos, G., Flier, J. S., & Maratos-Flier, E. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.002 · Cited by 1,495 · see citing works
FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis
Fisher, F. M., Kleiner, S., Douris, N., Fox, E. C., Mepani, R. J., Verdeguer, F., Wu, J., Kharitonenkov, A., Flier, J. S., Maratos-Flier, E., et al. (2012) · Genes & Development · doi:10.1101/gad.177857.111 · Cited by 1,478 · see citing works
Xu, J., Lloyd, D. J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., Vonderfecht, S., Hecht, R., Li, Y.-S., Lindberg, R. A., et al. (2009) · Diabetes · doi:10.2337/db08-0392 · Cited by 1,151 · see citing works
Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077 · see citing works
Fibroblast Growth Factor 21 Corrects Obesity in Mice
Coskun, T., Bina, H. A., Schneider, M. A., Dunbar, J. D., Hu, C. C., Chen, Y., Moller, D. E., & Kharitonenkov, A. (2008) · Endocrinology · doi:10.1210/en.2008-0816 · Cited by 1,031 · see citing works
Self-citationThe effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes
Gaich, G., Chien, J. Y., Fu, H., Glass, L. C., Deeg, M. A., Holland, W. L., Kharitonenkov, A., Bumol, T., Schilske, H. K., & Moller, D. E. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.08.005 · Cited by 885 · see citing works
Feldstein, A. E., Werneburg, N. W., Canbay, A. E., Guicciardi, M. E., Bronk, S. F., Rydzewski, R. M., Burgart, L. J., & Gores, G. J. (2004) · Hepatology · doi:10.1002/hep.20283 · Cited by 833 · see citing works
Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State
Fisher, F. M., Chui, P. C., Antonellis, P. J., Bina, H. A., Kharitonenkov, A., Flier, J. S., & Maratos-Flier, E. (2010) · Diabetes · doi:10.2337/db10-0193 · Cited by 830 · see citing works
Self-citationThe metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21
Kharitonenkov, A., Wroblewski, V. J., Koester, A., Chen, Y.-F., Clutinger, C. K., Tigno, X. T., Hansen, B. C., Shanafelt, A. B., & Etgen, G. J. (2007) · Endocrinology · doi:10.1210/en.2006-1168 · Cited by 738 · see citing works
Free Fatty Acids Induce JNK-dependent Hepatocyte Lipoapoptosis
Malhi, H., Bronk, S. F., Werneburg, N. W., & Gores, G. J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510660200 · Cited by 724 · see citing works
Potthoff, M. J., Inagaki, T., Satapati, S., Ding, X., He, T., Goetz, R., Mohammadi, M., Finck, B. N., Mangelsdorf, D. J., Kliewer, S. A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904187106 · Cited by 704 · see citing works
Lin, Z., Tian, H., Lam, K. S. L., Lin, S., Hoo, R. C. L., Konishi, M., Itoh, N., Wang, Y., Bornstein, S. R., Xu, A., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.005 · Cited by 691 · see citing works
Increased Fibroblast Growth Factor 21 in Obesity and Nonalcoholic Fatty Liver Disease
Dushay, J., Chui, P. C., Gopalakrishnan, G. S., Varela–Rey, M., Crawley, M., Fisher, F. M., Badman, M. K., Martinez–Chantar, M. L., & Maratos–Flier, E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.04.054 · Cited by 607 · see citing works
Hepatic histology in obese patients undergoing bariatric surgery
Machado, M. V., Marques-Vidal, P. M., & Cortez‐Pinto, H. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.06.013 · Cited by 577 · see citing works
An FGF21-Adiponectin-Ceramide Axis Controls Energy Expenditure and Insulin Action in Mice
Holland, W., Adams, A., Brozinick, J., Bui, H., Miyauchi, Y., Kusminski, C., Bauer, S., Wade, M., Singhal, E., Cheng, C. C., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.03.019 · Cited by 525 · see citing works
Mitochondrial abnormalities in non-alcoholic steatohepatitis
Caldwell, S. H., Swerdlow, R. H., Khan, E. M., Iezzoni, J. C., Hespenheide, E. E., Parks, J. K., & Parker, W. D. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80033-6 · Cited by 495 · see citing works
Prevalence of fatty liver in Japanese children and relationship to obesity
Tominaga, K., Kurata, J. H., Chen, Y. K., Fujimoto, E. K., Miyagawa, S., Abe, I., & Kusano, Y. (1995) · Digestive Diseases and Sciences · doi:10.1007/bf02208670 · Cited by 405 · see citing works
Berson, A., de Beco, V., Lettéron, P., Robin, M. A., Moreau, C., Elkahwaji, J. E., Verthier, N., Feldmann, G., Fromenty, B., & Pessayre, D. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70590-6 · Cited by 402 · see citing works
Li, H., Fang, Q., Gao, F., Fan, J., Zhou, J., Wang, X., Zhang, H., Pan, X., Bao, Y., Xiang, K., et al. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.05.018 · Cited by 400 · see citing works
Fibroblast Growth Factor 21-Deficient Mice Demonstrate Impaired Adaptation to Ketosis
Badman, M. K., Koester, A., Flier, J. S., Kharitonenkov, A., & Maratos-Flier, E. (2009) · Endocrinology · doi:10.1210/en.2009-0532 · Cited by 362 · see citing works
Self-citationMuise, E. S., Azzolina, B., Kuo, D. W., El-Sherbeini, M., Tan, Y., Yuan, X., Mu, J., Thompson, J. R., Berger, J. P., & Wong, K. K. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.044826 · Cited by 294 · see citing works
Li, Y., Wong, K., Giles, A. J., Jiang, J., Lee, J. W., Adams, A. C., Kharitonenkov, A., Yang, Q., Gao, B., Guarente, L., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.10.059 · Cited by 281 · see citing works
The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue
Adams, A. C., Yang, C., Coskun, T., Cheng, C. C., Gimeno, R. E., Luo, Y., & Kharitonenkov, A. (2013) · Molecular Metabolism · doi:10.1016/j.molmet.2012.08.007 · Cited by 266 · see citing works
Rizki, G., Arnaboldi, L., Gabrielli, B., Yan, J. S., Lee, G. S., Ng, R. K., Turner, S., Badger, T. M., Pitas, R. E., & Maher, J. J. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m600198-jlr200 · Cited by 257 · see citing works
Ables, G. P., Perrone, C. E., Orentreich, D. S., & Orentreich∥, N. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051357 · Cited by 241 · see citing works
Acyl-CoA synthesis, lipid metabolism and lipotoxicity
Li, L. O., Klett, E. L., & Coleman, R. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2009.09.024 · Cited by 241 · see citing works
Integrated Regulation of Hepatic Metabolism by Fibroblast Growth Factor 21 (FGF21) in Vivo
Fisher, F. M., Estall, J. L., Adams, A. C., Antonellis, P. J., Bina, H. A., Flier, J. S., Kharitonenkov, A., Spiegelman, B. M., & Maratos–Flier, E. (2011) · Endocrinology · doi:10.1210/en.2011-0281 · Cited by 229 · see citing works
Acyl-coenzyme A synthetases in metabolic control
Ellis, J. M., Frahm, J. L., Li, L. O., & Coleman, R. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833884bb · Cited by 228 · see citing works
Cellular Mechanisms by Which FGF21 Improves Insulin Sensitivity in Male Mice
Camporez, J. P., Jornayvaz, F. R., Petersen, M. C., Pesta, D. H., Guigni, B. A., Serr, J., Zhang, D., Kahn, M., Samuel, V. T., Jurczak, M. J., et al. (2013) · Endocrinology · doi:10.1210/en.2013-1191 · Cited by 226 · see citing works
Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease
Yilmaz, Y. N., Eren, F., Yönal, O., Kurt, R., Aktaş, B., Çelikel, Ç., Özdogan, O. C., İmeryüz, N., Kalaycı, C., & Avşar, E. (2010) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2010.02338.x · Cited by 196 · see citing works
Fibroblast Growth Factor 21 Reduces the Severity of Cerulein-Induced Pancreatitis in Mice
Johnson, C. L., Weston, J. Y., Chadi, S. A., Fazio, E. N., Huff, M. W., Kharitonenkov, A., Köester, A., & Pin, C. L. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.07.064 · Cited by 180 · see citing works
Natural History of NAFLD: Remarkably Benign in the Absence of Cirrhosis
Day, C. P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.05.041 · Cited by 176 · see citing works
Schattenberg, J. M., & Schuppan, D. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32834c7cfc · Cited by 119 · see citing works
Alisi, A., Ceccarelli, S., Panera, N., Prono, F., Petrini, S., Stefanis, C. D., Pezzullo, M., Tozzi, A. E., Villani, A., Bedogni, G., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067160 · Cited by 105 · see citing works
Review article: fructose in non‐alcoholic fatty liver disease
Yilmaz, Y. N. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2012.05080.x · Cited by 65 · see citing works
Nontriglyceride Hepatic Lipotoxicity: The New Paradigm for the Pathogenesis of NASH
Neuschwander‐Tetri, B. A. (2010) · Current Gastroenterology Reports · doi:10.1007/s11894-009-0083-6 · Cited by 63 · see citing works
Adams, S. H., Lin, X., Yu, X. X., Odle, J., & Drackley, J. K. (1997) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1997.272.5.r1641 · Cited by 26 · see citing works
Flagged first, then by citations
1 of the 44 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- [32]Potthoff MJ Inagaki T Satapati S Ding X He T Goetz R Mohammadi M Finck BN Mangelsdorf DJ Kliewer SA Burgess SC FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response Proceedings of the National Academy of Sciences of the United States of America 2009 106 10853 8 19541642 PMC2705613
Cited by
Sorted by citations
Understanding the Physiology of FGF21
Fisher, F. M., & Maratos-Flier, E. (2016) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021115-105339 · Cited by 912 · see citing works
Kalinkovich, A., & Livshits, G. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2016.09.008 · Cited by 882 · see citing works
Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD
Montagner, A., Polizzi, A., Fouché, E., Ducheix, S., Lippi, Y., Lasserre, F., Barquissau, V., Régnier, M., Lukowicz, C., Benhamed, F., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310798 · Cited by 746 · see citing works
Targeting adipose tissue in the treatment of obesity-associated diabetes
Kusminski, C. M., Bickel, P. E., & Scherer, P. E. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.75 · Cited by 678 · see citing works
The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic
Geng, L., Lam, K. S. L., & Xu, A. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0386-0 · Cited by 607 · see citing works
Targeting fibrosis: mechanisms and clinical trials
Zhao, M., Wang, L., Wang, M., Zhou, S., Lu, Y., Cui, H., Racanelli, A. C., Zhang, L., Ye, T., Ding, B., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01070-3 · Cited by 547 · see citing works
Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies
Musso, G., Cassader, M., & Gambino, R. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.3 · Cited by 415 · see citing works
An, P., Wei, L.-L., Zhao, S., Sverdlov, D. Y., Vaid, K. A., Miyamoto, M., Kuramitsu, K., Lai, M., & Popov, Y. V. (2020) · Nature Communications · doi:10.1038/s41467-020-16092-0 · Cited by 319 · see citing works
A Dozen Years of Discovery: Insights into the Physiology and Pharmacology of FGF21
Kliewer, S. A., & Mangelsdorf, D. J. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.01.004 · Cited by 273 · see citing works
Bile acids and their receptors in metabolic disorders
Fiorucci, S., Distrutti, E., Carino, A., Zampella, A., & Biagioli, M. (2021) · Progress in Lipid Research · doi:10.1016/j.plipres.2021.101094 · Cited by 262 · see citing works
Hepatokines and metabolism: Deciphering communication from the liver
Jensen-Cody, S. O., & Potthoff, M. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101138 · Cited by 252 · see citing works
Schlein, C., Talukdar, S., Heine, M., Fischer, A. W., Krott, L. M., Nilsson, S. K., Brenner, M. B., Heeren, J., & Scheja, L. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.01.006 · Cited by 252 · see citing works
Fructose ingestion acutely stimulates circulating FGF21 levels in humans
Dushay, J. R., Toschi, E., Mitten, E. K., Fisher, F. M., Herman, M. A., & Maratos-Flier, E. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2014.09.008 · Cited by 233 · see citing works
Tillman, E. J., & Rolph, T. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.601290 · Cited by 209 · see citing works
Metabolic adaptation in obesity and type ii diabetes: myokines, adipokines and hepatokines
Oh, K.-J., Lee, D., Kim, W., Han, B., Lee, S., & Bae, K.-H. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms18010008 · Cited by 210 · see citing works
Yamashita, S., Masuda, D., & Matsuzawa, Y. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-0823-5 · Cited by 191 · see citing works
Hepatic lipid accumulation: cause and consequence of dysregulated glucoregulatory hormones
Geisler, C. E., & Renquist, B. J. (2017) · Journal of Endocrinology · doi:10.1530/joe-16-0513 · Cited by 191 · see citing works
Gong, Q., Hu, Z., Zhang, F., Cui, A., Chen, X., Jiang, H., Gao, J., Chen, X., Han, Y., Liang, Q., et al. (2016) · Hepatology · doi:10.1002/hep.28523 · Cited by 172 · see citing works
A liver stress-endocrine nexus promotes metabolic integrity during dietary protein dilution
Maida, A., Zota, A., Sjøberg, K. A., Schumacher, J., Sijmonsma, T. P., Pfenninger, A., Christensen, M. M., Gantert, T., Fuhrmeister, J., Rothermel, U., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85946 · Cited by 170 · see citing works
Gariani, K., Ryu, D., Menzies, K. J., Yi, H.-S., Stein, S., Zhang, H., Perino, A., Lemos, V., Katsyuba, E., Jha, P., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.08.024 · Cited by 167 · see citing works
“Feeding mice with an MCD diet is known to induce severe liver steatosis, inflammation, oxidative stress, and mitochondrial damage, without the classical systemic features of NAFLD such as insulin resistance [46].”
BackgroundGoing Back to the Biology of FGF21: New Insights
Lewis, J. E., Ebling, F. J. P., Samms, R. J., & Tsintzas, K. (2019) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2019.05.007 · Cited by 164 · see citing works
A critical role for ChREBP-mediated FGF21 secretion in hepatic fructose metabolism
Fisher, F. M., Kim, M., Doridot, L., Cunniff, J. C., Parker, T. S., Levine, D. M., Hellerstein, M. K., Hudgins, L. C., Maratos-Flier, E., & Herman, M. A. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2016.11.008 · Cited by 166 · see citing works
Zhang, J., Cheng, Y., Gu, J., Wang, S., Zhou, S., Wang, Y., Tan, Y., Feng, W., Fu, Y., Mellen, N. M., et al. (2016) · Clinical Science · doi:10.1042/cs20150623 · Cited by 158 · see citing works
Fibroblast Activation Protein Cleaves and Inactivates Fibroblast Growth Factor 21
Dunshee, D. R., Bainbridge, T. W., Kljavin, N. M., Zavala-Solorio, J., Schroeder, A. C., Chan, R., Corpuz, R., Wong, M., Zhou, W., Deshmukh, G., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.710582 · Cited by 158 · see citing works
Tacke, F., & Weiskirchen, R. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4354 · Cited by 154 · see citing works
Cao, Y., Jiang, X., Ma, H., Wang, Y., Xue, P., & Liu, Y. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.08.022 · Cited by 152 · see citing works
FGF21: A Novel Regulator of Glucose and Lipid Metabolism and Whole-Body Energy Balance
Szczepańska, E., & Gietka‐Czernel, M. (2022) · Hormone and Metabolic Research · doi:10.1055/a-1778-4159 · Cited by 155 · see citing works
Desai, B. N., Singhal, G., Watanabe, M., Stevanovic, D., Lundasen, T., Fisher, F. M., Mather, M. L., Vardeh, H. G., Douris, N., Adams, A. C., et al. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.08.004 · Cited by 150 · see citing works
Self-citationMetabolic Targets in Nonalcoholic Fatty Liver Disease
Esler, W. P., & Bence, K. K. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2019.04.007 · Cited by 142 · see citing works
Amino Acid Sensing in Metabolic Homeostasis and Health.
Hu, X.-M., & Guo, F. (2020) · Endocrine reviews · doi:10.1210/endrev/bnaa026 · Cited by 123 · see citing works
Li, X. (2019) · Frontiers of Medicine · doi:10.1007/s11684-019-0711-y · Cited by 139 · see citing works
Hepatocyte-specific deletion of Pparα promotes NAFLD in the context of obesity
Régnier, M., Polizzi, A., Smati, S., Lukowicz, C., Fougerat, A., Lippi, Y., Fouché, E., Lasserre, F., Naylies, C., Bétoulières, C., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-63579-3 · Cited by 141 · see citing works
Cusi, K. J. (2016) · Diabetologia · doi:10.1007/s00125-016-3952-1 · Cited by 138 · see citing works
Fibroblast growth factor 21 in non-alcoholic fatty liver disease
Tucker, B., Li, H., Long, X., Rye, K., & Ong, K. L. (2019) · Metabolism · doi:10.1016/j.metabol.2019.153994 · Cited by 132 · see citing works
Kaufman, A., Abuqayyas, L., Denney, W. S., Tillman, E. J., & Rolph, T. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100057 · Cited by 131 · see citing works
Emerging Liver–Kidney Interactions in Nonalcoholic Fatty Liver Disease
Musso, G., Cassader, M., Cohney, S. J., Pinach, S., Saba, F., & Gambino, R. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.08.005 · Cited by 132 · see citing works
Inflammation initiates a vicious cycle between obesity and nonalcoholic fatty liver disease
Luo, Y., & Lin, H. (2020) · Immunity Inflammation and Disease · doi:10.1002/iid3.391 · Cited by 127 · see citing works
Komatsu, M., Kanda, T., Urai, H., Kurokochi, A., Kitahama, R., Shigaki, S., Ono, T., Yukioka, H., Hasegawa, K., Tokuyama, H., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-26882-8 · Cited by 126 · see citing works
Fibroblast growth factor 21: a regulator of metabolic disease and health span
Xie, T., & Leung, P. S. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00101.2017 · Cited by 121 · see citing works
Yap, Y. W., Rusu, P. M., Chan, A. Y., Fam, B. C., Jungmann, A., Solon‐Biet, S. M., Barlow, C. K., Creek, D. J., Huang, C., Schittenhelm, R. B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16568-z · Cited by 118 · see citing works
Targeting FGF21 in cardiovascular and metabolic diseases: from mechanism to medicine
Tan, H., Tong, Y. A., Chen, Z., Wu, W., Xu, S., & Weng, J. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.73936 · Cited by 119 · see citing works
Tanaka, N., Takahashi, S., Zhang, Y., Krausz, K. W., Smith, P. B. W., Patterson, A. D., & Gonzalez, F. J. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.02.012 · Cited by 120 · see citing works
FGF21 Revolutions: Recent Advances Illuminating FGF21 Biology and Medicinal Properties
Kharitonenkov, A., & DiMarchi, R. D. (2015) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2015.09.007 · Cited by 114 · see citing works
Longo, M., Meroni, M., Paolini, E., Macchi, C., & Dongiovanni, P. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154708 · Cited by 112 · see citing works
Singhal, G., Fisher, F. M., Chee, M. J. S., Tan, T. G., Ouaamari, A. E., Adams, A. C., Najarían, R. M., Kulkarni, R., Benoist, C. O., Flier, J. S., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0148252 · Cited by 112 · see citing works
Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy
Wang, L., Cai, Y., Jian, L., Cheung, C. W., Zhang, L., & Xia, Z. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01188-0 · Cited by 114 · see citing works
Loomba, R. S., Sanyal, A. J., Nakajima, A., Neuschwander‐Tetri, B. A., Goodman, Z. D., Harrison, S. A., Lawitz, E., Gunn, N., Imajo, K., Ravendhran, N., et al. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.04.011 · Cited by 111 · see citing works
Harrison, S. A., Ruane, P. J., Freilich, B., Neff, G., Patil, R., Behling, C., Hu, C., Shringarpure, R., de Temple, B., Fong, E., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2022.100563 · Cited by 110 · see citing works
Geller, S., Arribat, Y., Netzahualcoyotzi, C., Lagarrigue, S., Carneiro, L., Zhang, L., Amati, F., López‐Mejía, I. C., & Pellerin, L. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.08.004 · Cited by 108 · see citing works
FGF21-receptor agonists: an emerging therapeutic class for obesity-related diseases
Sonoda, J., Chen, M. Z., & Baruch, A. (2017) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2017-0002 · Cited by 106 · see citing works
Valdecantos, M. P., Pardo, V., Ruiz, L., Castro‐Sánchez, L., Lanzón, B., Fernández‐Millán, E., García‐Monzón, C., Arroba, A. I., González‐Rodríguez, Á., Escrivá, F., et al. (2017) · Hepatology · doi:10.1002/hep.28962 · Cited by 100 · see citing works
Hou, T., Tian, Y., Cao, Z., Zhang, J., Feng, T., Tao, W., Sun, H., Wen, H., Lu, X., Zhu, Q., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.09.018 · Cited by 106 · see citing works
Fibroblast growth factor 21 night watch: advances and uncertainties in the field
Kharitonenkov, A., & DiMarchi, R. D. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12580 · Cited by 97 · see citing works
The role of FGF21 and its analogs on liver associated diseases
Falamarzi, K., Malekpour, M., Tafti, M. F., Azarpira, N., Behboodi, M., & Zarei, M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.967375 · Cited by 94 · see citing works
The Role of Gut Microbiome-Derived Short-Chain Fatty Acid Butyrate in Hepatobiliary Diseases
Pant, K., Venugopal, S. K., Pisarello, M. J. L., & Gradilone, S. A. (2023) · American Journal Of Pathology · doi:10.1016/j.ajpath.2023.06.007 · Cited by 96 · see citing works
Bao, L., Yin, J., Gao, W., Wang, Q., Yao, W., & Gao, X.-D. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14383 · Cited by 83 · see citing works
Henriksson, E., & Andersen, B. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.601349 · Cited by 95 · see citing works
PPARs and Mitochondrial Metabolism: From NAFLD to HCC
Mello, T., Materozzi, M., & Galli, A. (2016) · PPAR Research · doi:10.1155/2016/7403230 · Cited by 92 · see citing works
Targeting FGF21 for the Treatment of Nonalcoholic Steatohepatitis
Zarei, M., Pizarro‐Delgado, J., Barroso, E., Palomer, X., & Vázquez‐Carrera, M. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.12.005 · Cited by 92 · see citing works
FGF21 in obesity and cancer: New insights
Lu, W., Li, X., & Luo, Y. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.11.026 · Cited by 92 · see citing works
Singhal, G., Kumar, G., Chan, S., Fisher, F. M., Ma, Y., Vardeh, H. G., Nasser, I. A., Flier, J. S., & Maratos-Flier, E. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.03.002 · Cited by 87 · see citing works
Self-citationWei, G., An, P., Vaid, K. A., Nasser, I., Huang, P., Tan, L., Zhao, S., Schuppan, D., & Popov, Y. V. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00041.2019 · Cited by 84 · see citing works
Hepatokines and non-alcoholic fatty liver disease
Lebensztejn, D. M., Flisiak-Jackiewicz, M., Białokoz-Kalinowska, I., Bobrus-Chociej, A., & Kowalska, I. (2016) · Acta Biochimica Polonica · doi:10.18388/abp.2016_1252 · Cited by 90 · see citing works
“It affects selected elements of the “multi-hits theory”, such as oxidative stress, endoplasmic reticulum stress, mitochondrial dysfunction, and low-grade chronic inflammation (Nishimura et al., 2000; Jiang et al., 2014; Fisher et al., 2014; Kim et al., 2015).”
BackgroundNew drugs for NAFLD: lessons from basic models to the clinic
Reimer, K. C., Wree, A., Roderburg, C., & Tacke, F. (2019) · Hepatology International · doi:10.1007/s12072-019-10001-4 · Cited by 83 · see citing works
Lu, P., Yan, J., Liu, K., Garbacz, W. G., Wang, P., Xu, M., Ma, X., & Xie, W. (2015) · Hepatology · doi:10.1002/hep.27719 · Cited by 79 · see citing works
FGF21 reverses MASH through coordinated actions on the CNS and liver
Rose, J. P., Morgan, D. A., Sullivan, A. I., Fu, X., Inigo-Vollmer, M., Burgess, S. C., Meyerholz, D. K., Rahmouni, K., & Potthoff, M. J. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.04.014 · Cited by 75 · see citing works
An update on the recent advances in antifibrotic therapy
Tacke, F., & Weiskirchen, R. (2018) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2018.1530110 · Cited by 78 · see citing works
Pathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic Approaches
Kim, K. H., & Lee, M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00485 · Cited by 77 · see citing works
Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities
Manka, P. P., Zeller, A. C., & Syn, W. (2019) · Drugs · doi:10.1007/s40265-019-01126-9 · Cited by 77 · see citing works
The potential function and clinical application of FGF21 in metabolic diseases
Chen, Z., Yang, L., Liu, Y., Huang, P., Song, H., & Zheng, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1089214 · Cited by 72 · see citing works
Liu, C., Schönke, M., Spoorenberg, B., Lambooij, J. M., van der Zande, H. J. P., Zhou, E., Tushuizen, M. E., Andréasson, A., Park, A., Oldham, S. N., et al. (2023) · eLife · doi:10.7554/elife.83075 · Cited by 72 · see citing works
Regulation of Hepatic Stellate Cells and Fibrogenesis by Fibroblast Growth Factors
Schumacher, J. D., & Guo, G. L. (2016) · BioMed Research International · doi:10.1155/2016/8323747 · Cited by 70 · see citing works
Zhou, S., You, H., Qiu, S., Yu, D., Bai, Y., He, J., Cao, H., Che, Q., Guo, J., & Su, Z. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113577 · Cited by 70 · see citing works
Fibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders
Zhang, J., & Li, Y. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00168 · Cited by 70 · see citing works
Rader, D. J., Maratos-Flier, E., Nguyen, A., Hom, D., Ferriere, M., Li, Y., Kompa, J., Martic, M., Hinder, M., Basson, C. T., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab624 · Cited by 72 · see citing works
Pan, Y., Wang, B., Zheng, J., Xiong, R., Fan, Z., Ye, Y., Zhang, S., Li, Q., Gong, F., Wu, C., et al. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14007 · Cited by 67 · see citing works
Yamashita, S., Masuda, D., & Matsuzawa, Y. (2019) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.48918 · Cited by 68 · see citing works
Role of fibroblast growth factor signalling in hepatic fibrosis
Seitz, T., & Hellerbrand, C. (2021) · Liver International · doi:10.1111/liv.14863 · Cited by 64 · see citing works
Song, L., Wang, L., Hou, Y., Zhou, J., Chuchu, C., Ye, X., Dong, W., Gao, H. F., Liu, Y., Qiao, G., et al. (2022) · Hepatology · doi:10.1002/hep.32404 · Cited by 65 · see citing works
FGF21 as a mediator of adaptive responses to stress and metabolic benefits of anti-diabetic drugs
Kim, K. H., & Lee, M. (2015) · Journal of Endocrinology · doi:10.1530/joe-15-0160 · Cited by 63 · see citing works
Fatty liver and FGF21 physiology
Maratos–Flier, E. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.05.006 · Cited by 64 · see citing works
Schumacher, J. D., & Guo, G. L. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_228 · Cited by 64 · see citing works
Yano, K., Yamaguchi, K., Seko, Y., Okishio, S., Ishiba, H., Tochiki, N., Takahashi, A., Kataoka, S., Okuda, K., Liu, Y. X., et al. (2021) · Laboratory Investigation · doi:10.1038/s41374-021-00680-9 · Cited by 63 · see citing works
Gilroy, C. A., Roberts, S., & Chilkoti, A. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.03.015 · Cited by 58 · see citing works
Zeng, K., Tian, L., Patel, R., Shao, W., Song, Z., Liu, L., Manuel, J., Ma, X., McGilvray, I. D., Cummins, C. L., et al. (2016) · Endocrinology · doi:10.1210/en.2016-1596 · Cited by 57 · see citing works
Liu, X.-Y., Henkel, A. S., LeCuyer, B. E., Schipma, M., Anderson, K., & Green, R. (2015) · American Journal of Physiology - Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00132.2015 · Cited by 50 · see citing works
Somm, E., Henry, H., Bruce, S. J., Aeby, S., Rosikiewicz, M., Sykiotis, G. P., Asrih, M., Jornayvaz, F. R., Denechaud, P., Albrecht, U., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.91809 · Cited by 57 · see citing works
An, P., Wei, G., Huang, P., Li, W., Qi, X., Lin, Y., Vaid, K. A., Wang, J., Zhang, S., Li, Y., et al. (2020) · Liver International · doi:10.1111/liv.14490 · Cited by 57 · see citing works
Forced Hepatic Overexpression of CEACAM1 Curtails Diet-Induced Insulin Resistance
Al–Share, Q. Y., DeAngelis, A. M., Lester, S. G., Bowman, T. A., Ramakrishnan, S. K., Abdallah, S. L., Russo, L., Patel, P. R., Kaw, M., Raphael, C. K., et al. (2015) · Diabetes · doi:10.2337/db14-1772 · Cited by 56 · see citing works
Cui, A., Li, J., Ji, S., Ma, F., Wang, G., Xue, Y., Liu, Z., Gao, J., Han, J. S., Tai, P., et al. (2020) · Diabetes · doi:10.2337/db20-0209 · Cited by 56 · see citing works
Multiple organs involved in the pathogenesis of non-alcoholic fatty liver disease
Li, X., & Wang, H. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00507-y · Cited by 46 · see citing works
Inagaki, T. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00147 · Cited by 55 · see citing works
Rush to the fire: FGF21 extinguishes metabolic stress, metaflammation and tissue damage
Luo, Y., Ye, S., Chen, X., Gong, F., Lu, W., & Li, X. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.08.001 · Cited by 55 · see citing works
Fibroblast growth factor 21 in chronic kidney disease
Suassuna, P. G. D. A., de Paula, R. B., Sanders‐Pinheiro, H., Moe, O. W., & Hu, M. C. (2018) · Journal of Nephrology · doi:10.1007/s40620-018-0550-y · Cited by 57 · see citing works
Harris, L.-A. L. S., Smith, G. I., Patterson, B. W., Ramaswamy, R. S., Okunade, A. L., Kelly, S. C., Porter, L. C., Klein, S., Yoshino, J., & Mittendorfer, B. (2017) · Diabetes · doi:10.2337/db16-1475 · Cited by 53 · see citing works
Hashidume, T., Kato, A., Tanaka, T., Miyoshi, S., Itoh, N., Nakata, R., Inoue, H., Oikawa, A., Nakai, Y., Shimizu, M., et al. (2016) · Scientific Reports · doi:10.1038/srep28183 · Cited by 52 · see citing works
Martin, A., Ecklu-Mensah, G., Ha, C. W. Y., Hendrick, G., Layman, D. K., Gilbert, J. A., & Devkota, S. (2021) · Nature Communications · doi:10.1038/s41467-021-24074-z · Cited by 52 · see citing works
Fibroblast Growth Factor 21 Mediates Glycemic Regulation by Hepatic JNK
Vernia, S., Cavanagh, J., Barrett, T., Tournier, C., & Davis, R. J. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.02.026 · Cited by 48 · see citing works
Wu, G., Li, H., Fang, Q., Zhang, J., Zhang, M., Zhang, L., Wu, L., Hou, X., Lu, J., Bao, Y., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-05257-5 · Cited by 49 · see citing works
Liu, D., Pang, J., Shao, W., Gu, J., Zeng, Y., He, H. H., Ling, W., Qian, X., & Jin, T. (2021) · Hepatology · doi:10.1002/hep.31856 · Cited by 48 · see citing works
- Authors
- Fisher, F. M., Chui, P. C., Nasser, I. A., Popov, Y., Cunniff, J. C., Lundasen, T., Kharitonenkov, A., Schuppan, D., Flier, J. S., & Maratos-Flier, E.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Eli Lilly (United States) (US)
- Corresponding author
- Fisher, Ffolliott M.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2014-11
- Volume
- 147
- Issue
- 5
- Pages
- 1073-1083.e6
- ISSN
- 0016-5085 (ISSN-L)
- PMC
- PMC4570569
- OpenAlex
- W1984913749
- Cited by
- 263
- References
- 44
- Citations by year
- 2026: 14 · 2025: 14 · 2024: 13 · 2023: 21 · 2022: 25 · 2021: 32 · 2020: 28 · 2019: 24 · 2018: 20 · 2017: 21 · 2016: 30 · 2015: 17 · 2014: 2
- FWCI
- 9.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- FGF21, lipotoxicity, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, fatty acid beta-oxidation, hepatic steatosis, liver fibrosis, oxidative stress, free fatty acids, FGF21 knockout mice, high-fat diet
- MeSH terms
- Animals, Choline Deficiency, Disease Models, Animal, Fatty Acids, Fibroblast Growth Factors, Hepatitis, Liver, Liver Cirrhosis, Methionine, Mice, Inbred C57BL, Oxidation-Reduction, Recombinant Proteins, RNA, Messenger, Severity of Illness Index, Time Factors, Lipid Peroxidation, Mice, Knockout, Disease Progression, Inflammation Mediators, Infusions, Subcutaneous, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
